Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of growth hormone after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency
NL-OMON55366Completed
- Sponsor
- Erasmus MC
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of somatropin in growth hormone deficiency (GHD) and Idiopathic Isolated Growth Hormone Deficiency (IGHD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Adult height minus target height SDS. Started Apr 2017; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)Idiopathic Isolated Growth Hormone Deficiency (IGHD)
Beyond the preview
Go deeper on NL-OMON55366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55366.